1. Home
  2. /
  3. Projects
  4. /
  5. Page 3

Epidemiological impact

Evaluating infectious disease prevention over the long term: implications of analytic horizon and scenario choices

A lifetime time horizon is conventional for cost-effectiveness analysis, but not routine for transmission-dynamic modeling given uncertainty in epidemiological dynamics and high computational costs. We demonstrate how choices about time horizon and analytic scenarios can influence cost-effectiveness estimates, using a case study of novel tuberculosis (TB) vaccine introduction.

IGRA prevalence study

 A cross-sectional study to determine IGRA positivity rate to assess eligibility for participation in tuberculosis (TB) vaccine efficacy trials

Modelling to estimate the health impact of novel tuberculosis vaccines on TB burden in people living with HIV

This project will inform tuberculosis (TB) prevention efforts by estimating the health impact of novel tuberculosis vaccines on TB burden in people living with HIV (PLHIV) using a novel Mycobacterium tuberculosis transmission model. HIV confers the largest relative risk of TB, and new TB vaccines could be an important tool to prevent TB; however, modelling studies have not systematically investigated how new vaccines will affect TB burden in PLHIV. In stage 1 of this project, we aim to investigate TB vaccine impact in PLHIV where vaccine product characteristics and delivery vary by recipient HIV status. In stage 2, we aim to quantify how complex vaccine targeting strategies and incorporating additional granularity in HIV/AIDS natural history might affect vaccine impact estimates in PLHIV

Evaluating vaccination strategies for tuberculosis in endemic and non-endemic settings

We propose a continuous age-structured model for the epidemiology of tuberculosis with pre- and post-exposure vaccination. We use uncertainty and sensitivity analysis to make predictions about the efficacy of different vaccination strategies in a non-endemic setting (United States) and an endemic setting (Cambodia). In particular, we determine optimal age groups to target for pre-exposure and post-exposure vaccination in both settings.
Click to copy link of this header Menu